LDH Isotyping for Checkpoint Inhibitor Response Prediction in Patients with Metastatic Melanoma

Serum lactate dehydrogenase (LDH) levels are inversely related with response to immune checkpoint inhibitors (ICIs) in patients metastatic melanoma. LDH is a key regulator of glycolysis, pathway known be upregulated malignant tumors and negatively affect antitumor immunity. We hypothesized that isotype distribution peripheral blood better reflects tumor glycolytic activity than total might therefore contribute immunotherapy prediction. isotyping was performed 40 melanoma elevated levels, which 22 were treated ipilimumab plus nivolumab. LDH-1 decreased 57.5% patients. The percentage LDH-2, -3 -4, on the other hand, 35%, 67.5% 37.5% patients, respectively. There no difference between versus without clinical benefit ICIs, except for numerically lower (median 13.3% vs. 17.6%, p = 0.1295). correlated burden not likely have strong, independent predictive value ICIs. In conclusion, does ICI prediction levels.